Jie Zhou1, Shubin Qi2, Xiang Gao3, Shenling Li4, Tingting Zhang1. 1. Department of Traditional Chinese Medicine, The Affiliated Hospital of Qingdao University Qingdao, Shandong Province, China. 2. Department of Spine Surgery, Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital) Qingdao, Shandong Province, China. 3. Department of Allergy, The Affiliated Hospital of Qingdao University Qingdao, Shandong Province, China. 4. Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Qingdao University Qingdao, Shandong Province, China.
Abstract
OBJECTIVE: To investigate the clinical efficacy of Jade Wind-Barrier Powder combined with Loratadine in the treatment of pediatric allergic rhinitis (PAR). METHODS: The clinical data of 101 children with allergic rhinitis (AR) admitted to the Affiliated Hospital of Qingdao University and Affiliated Hospital of Nanjing University of Traditional Chinese Medicine from January 2019 to December 2019 were retrospectively analyzed. The children were randomly divided into Group A (n=50) and Group B (n=51) in accordance with a random number table. Group A was treated with Loratadine only, while Group B was treated with Loratadine combined with Jade Wind-Barrier powder. The clinical efficacy, symptom disappearance time, symptom scores before and after treatment, indices of immunological function, changes in the indices of inflammatory factors and disease recurrence were compared between the two groups. RESULTS: The overall response rate (ORR) in Group B (96.08%) was higher than that in Group A (76.00%) (P < 0.05). The disappearance time of sneezing, stuffy nose, runny nose and itchy nose in Group B was shorter than that in Group A (P < 0.05). After treatment, Group B exhibited lower symptom scores for sneezing, stuffy nose, runny nose and itchy nose, lower levels of IL-13, IL-4 and TNF-α, and higher CD4+CD25+, CD19+ and CD8+ than Group A (P < 0.05). The recurrence rate in Group B (3.92%) was lower than that in Group A (26.00%) (P < 0.05). CONCLUSION:Jade Wind-Barrier powder combined with Loratadine can improve clinical symptoms, immunity, inflammation levels and disease recurrence rate of PAR patients, with a significant clinical efficacy. AJTR
RCT Entities:
OBJECTIVE: To investigate the clinical efficacy of Jade Wind-Barrier Powder combined with Loratadine in the treatment of pediatric allergic rhinitis (PAR). METHODS: The clinical data of 101 children with allergic rhinitis (AR) admitted to the Affiliated Hospital of Qingdao University and Affiliated Hospital of Nanjing University of Traditional Chinese Medicine from January 2019 to December 2019 were retrospectively analyzed. The children were randomly divided into Group A (n=50) and Group B (n=51) in accordance with a random number table. Group A was treated with Loratadine only, while Group B was treated with Loratadine combined with Jade Wind-Barrier powder. The clinical efficacy, symptom disappearance time, symptom scores before and after treatment, indices of immunological function, changes in the indices of inflammatory factors and disease recurrence were compared between the two groups. RESULTS: The overall response rate (ORR) in Group B (96.08%) was higher than that in Group A (76.00%) (P < 0.05). The disappearance time of sneezing, stuffy nose, runny nose and itchy nose in Group B was shorter than that in Group A (P < 0.05). After treatment, Group B exhibited lower symptom scores for sneezing, stuffy nose, runny nose and itchy nose, lower levels of IL-13, IL-4 and TNF-α, and higher CD4+CD25+, CD19+ and CD8+ than Group A (P < 0.05). The recurrence rate in Group B (3.92%) was lower than that in Group A (26.00%) (P < 0.05). CONCLUSION: Jade Wind-Barrier powder combined with Loratadine can improve clinical symptoms, immunity, inflammation levels and disease recurrence rate of PAR patients, with a significant clinical efficacy. AJTR
Authors: E Skylogianni; M Triga; K Douros; K Bolis; K N Priftis; S Fouzas; M B Anthracopoulos Journal: Allergol Immunopathol (Madr) Date: 2018-01-12 Impact factor: 1.667
Authors: Luis Fernando Giraldo-Cadavid; Karen Perdomo-Sanchez; Jorge Luis Córdoba-Gravini; Maria Isabel Escamilla; Miguel Suarez; Natalia Gelvez; David Gozal; Elida Duenas-Meza Journal: Chest Date: 2019-10-04 Impact factor: 9.410
Authors: Francesco Maria Passali; Maria Carla Spinosi; Giulia Mignacco; Cemal Cingi; Hugo Anibal Rodriguez; Desiderio Passali Journal: Otolaryngol Pol Date: 2018-04-30
Authors: Michelle J Suh; Jin A Park; Suk Won Chang; Jeong Hong Kim; Keun-Hwa Lee; Seong-Chul Hong; Hye-Sook Lee; Ju Wan Kang Journal: PLoS One Date: 2019-01-17 Impact factor: 3.240